GENUITI
DEAD

Serial Number

98562943

Owner

GENUITI THERAPEUTICS, INC.

Attorney

Aaron D. Hendelman

Filing Date

May 22, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GENUITI Trademark

Serial Number: 98562943

GENUITI is a trademark filed by GENUITI THERAPEUTICS, INC. on May 22, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

GENUITI THERAPEUTICS, INC.

31 Old Farm Road
Lincoln, MA 01773

Entity Type: 03

Trademark Details

Filing Date

May 22, 2024

Registration Date

Not Registered

Goods & Services

scientific research for medical purposes in the fields of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development of therapeutics for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of small molecule drug discovery; medical and scientific research in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products development in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; drug discovery services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical research and development services in the field of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; research and development in the field of precision medicine; none of the foregoing for use related to DNA or RNA screening or analysis services or software

therapeutic pharmaceuticals for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical products for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceutical preparations for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; pharmaceuticals comprising small molecules for the treatment of obesity and metabolic diseases, eye diseases, mitochondrial diseases, pulmonary hypertension, metabolic syndromes; none of the foregoing for use related to DNA or RNA screening or analysis services or software

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 30, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 30, 2025 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 15, 2025 GNFN
FINAL REFUSAL E-MAILED
Sep 15, 2025 GNFR
FINAL REFUSAL WRITTEN
Sep 15, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 16, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 16, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 12, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 12, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 15, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 15, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 15, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 5, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 27, 2024 NWOS
NEW APPLICATION ENTERED
May 22, 2024 NWAP